Pharmaniaga Berhad (KLSE:PHARMA)
Malaysia · Delayed Price · Currency is MYR 0.2500
+0.0100 (4.17%)
At close: May 19, 2026
Pharmaniaga Berhad Income Statement
Financials in millions MYR. Fiscal year is January - December.
Millions MYR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 4,051 | 3,928 | 3,759 | 3,404 | 3,481 | 4,815 | |
Revenue Growth (YoY) | 5.22% | 4.48% | 10.43% | -2.20% | -27.71% | 76.69% |
Cost of Revenue | 3,641 | 3,519 | 3,219 | 3,097 | 3,138 | 4,185 |
Gross Profit | 410.1 | 409.16 | 540.49 | 307.82 | 342.72 | 630.02 |
Selling, General & Admin | 261.25 | 253.89 | 251.96 | 299.58 | 292.6 | 301.56 |
Amortization of Goodwill & Intangibles | 4.09 | 4.09 | 4.07 | 5.64 | 5.17 | 3.61 |
Operating Expenses | 286.87 | 279.51 | 279.57 | 328.27 | 314.72 | 322.64 |
Operating Income | 123.24 | 129.65 | 260.93 | -20.45 | 28 | 307.37 |
Interest Expense | -54.14 | -61.35 | -71.97 | -61.84 | -40.04 | -33.32 |
Interest & Investment Income | 6.42 | 5.66 | 2.25 | 1.48 | 0.91 | 1.52 |
Currency Exchange Gain (Loss) | - | - | - | 1.13 | 0.04 | 0.93 |
Other Non Operating Income (Expenses) | -0.14 | 0.51 | 2.89 | 0.66 | 3.03 | 0.51 |
EBT Excluding Unusual Items | 75.38 | 74.47 | 194.1 | -79.03 | -8.06 | 277 |
Impairment of Goodwill | - | - | - | - | -50.27 | - |
Gain (Loss) on Sale of Assets | 0.27 | 0.27 | 0.08 | 0.86 | 0.05 | 0.07 |
Asset Writedown | - | - | - | - | -552.31 | - |
Pretax Income | 75.64 | 74.74 | 194.18 | -78.16 | -610.59 | 277.08 |
Income Tax Expense | 23.02 | 24.05 | 60.39 | 0.58 | 17.07 | 104.87 |
Earnings From Continuing Operations | 52.63 | 50.68 | 133.79 | -78.74 | -627.65 | 172.21 |
Minority Interest in Earnings | -2.22 | -2.17 | -1.97 | -1.42 | -2.27 | -0.06 |
Net Income | 50.4 | 48.51 | 131.82 | -80.16 | -629.92 | 172.15 |
Net Income to Common | 50.4 | 48.51 | 131.82 | -80.16 | -629.92 | 172.15 |
Net Income Growth | -62.87% | -63.20% | - | - | - | 526.25% |
Shares Outstanding (Basic) | 4,892 | 3,614 | 1,441 | 1,368 | 1,310 | 1,309 |
Shares Outstanding (Diluted) | 4,892 | 3,614 | 1,441 | 1,368 | 1,310 | 1,309 |
Shares Change (YoY) | 239.34% | 150.74% | 5.38% | 4.40% | 0.05% | 0.04% |
EPS (Basic) | 0.01 | 0.01 | 0.09 | -0.06 | -0.48 | 0.13 |
EPS (Diluted) | 0.01 | 0.01 | 0.09 | -0.06 | -0.48 | 0.13 |
EPS Growth | -89.08% | -85.35% | - | - | - | 526.09% |
Free Cash Flow | -90.61 | -47.47 | 11.51 | -3.72 | -201.6 | -94.44 |
Free Cash Flow Per Share | -0.02 | -0.01 | 0.01 | -0.00 | -0.15 | -0.07 |
Dividend Per Share | - | - | - | - | 0.019 | 0.093 |
Dividend Growth | - | - | - | - | -79.57% | 322.73% |
Gross Margin | 10.12% | 10.42% | 14.38% | 9.04% | 9.85% | 13.08% |
Operating Margin | 3.04% | 3.30% | 6.94% | -0.60% | 0.80% | 6.38% |
Profit Margin | 1.24% | 1.23% | 3.51% | -2.35% | -18.10% | 3.57% |
Free Cash Flow Margin | -2.24% | -1.21% | 0.31% | -0.11% | -5.79% | -1.96% |
EBITDA | 144.06 | 154.29 | 288.49 | 7.35 | 55.62 | 335.28 |
EBITDA Margin | 3.56% | 3.93% | 7.67% | 0.22% | 1.60% | 6.96% |
D&A For EBITDA | 20.83 | 24.64 | 27.57 | 27.79 | 27.62 | 27.9 |
EBIT | 123.24 | 129.65 | 260.93 | -20.45 | 28 | 307.37 |
EBIT Margin | 3.04% | 3.30% | 6.94% | -0.60% | 0.80% | 6.38% |
Effective Tax Rate | 30.43% | 32.18% | 31.10% | - | - | 37.85% |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.